Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential gene expression in B cells and T helper cells following high-dose glucocorticoid therapy for multiple sclerosis relapse.
Hecker M, Fitzner B, Koczan D, Klehmet J, Grothe M, Schwab M, Winkelmann A, Meister S, Dudesek A, Ludwig-Portugall I, Eulitz K, Zettl UK. Hecker M, et al. Among authors: klehmet j. Biomed Pharmacother. 2024 Jun;175:116721. doi: 10.1016/j.biopha.2024.116721. Epub 2024 May 14. Biomed Pharmacother. 2024. PMID: 38749180 Free article.
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.
Krause N, Derad C, von Glasenapp B, Riemann-Lorenz K, Temmes H, van de Loo M, Friede T, Asendorf T, Heesen C; POWER@MS1 study group. Krause N, et al. Mult Scler Relat Disord. 2023 Nov;79:105043. doi: 10.1016/j.msard.2023.105043. Epub 2023 Oct 5. Mult Scler Relat Disord. 2023. PMID: 37839367 Free article. Clinical Trial.
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials.
Bayas A, Christ M, Faissner S, Klehmet J, Pul R, Skripuletz T, Meuth SG. Bayas A, et al. Among authors: klehmet j. Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221146836. doi: 10.1177/17562864221146836. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36710720 Free PMC article. Review.
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
Klehmet J, Begus-Nahrmann Y, Taipale K, Niemczyk G, Rehberg-Weber K. Klehmet J, et al. Ther Adv Neurol Disord. 2023 Dec 15;16:17562864231214041. doi: 10.1177/17562864231214041. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 38107443 Free PMC article.
[Public health situation of CIDP patients in nine German centers-neuritis network Germany].
Fisse AL, Motte J, Grüter T, Kohle F, Kronlage C, Stahl JH, Winter N, Seeliger T, Gingele S, Stascheit F, Hotter B, Klehmet J, Kummer K, Enax-Krumova EK, Sturm D, Skripuletz T, Schmidt J, Yoon MS, Pitarokoili K, Lehmann HC, Grimm A; Mitglieder des Neuritis Netz. Fisse AL, et al. Among authors: klehmet j. Nervenarzt. 2023 Apr;94(4):320-326. doi: 10.1007/s00115-022-01377-0. Epub 2022 Aug 23. Nervenarzt. 2023. PMID: 35997784 Free PMC article. German.
39 results